CONMED Stock (NYSE:CNMD)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$38.46

52W Range

$35.37 - $62.41

50D Avg

$41.93

200D Avg

$47.25

Market Cap

$1.19B

Avg Vol (3M)

$572.81K

Beta

0.90

Div Yield

$0.60 (2.08%)

CNMD Company Profile


CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

3,900

IPO Date

Jul 23, 1987

Website

CNMD Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
General Surgery$800.13M$763.03M$711.59M
Orthopedic Surgery$574.60M$543.99M$533.16M

Fiscal year ends in Dec 25 | Currency in USD

CNMD Financial Summary


Dec 25Dec 24Dec 23
Revenue$1.37B$1.31B$1.24B
Operating Income$130.13M$200.33M$120.60M
Net Income$47.05M$132.42M$64.46M
EBITDA$176.84M$272.18M$192.48M
Basic EPS$1.52$4.29$2.10
Diluted EPS$1.51$4.26$2.04

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Jan 28, 26 | 4:30 PM
Q3 25Nov 05, 25 | 4:30 PM
Q2 25Jul 30, 25 | 4:30 PM

Peer Comparison


TickerCompany
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.
SSIISS Innovations International, Inc.
ESTAEstablishment Labs Holdings Inc.
AHCOAdaptHealth Corp.
NEOGNeogen Corporation
NTLAIntellia Therapeutics, Inc.
UFPTUFP Technologies, Inc.
INMDInMode Ltd.
AZTAAzenta, Inc.
NVCRNovoCure Limited